NEW YORK, Jan. 8, 2024 /PRNewswire/ -- The castration-resistant prostate cancer (CRPC) treatment market is expected to grow by USD 5.98 billion from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of 8.83% during the forecast period, according to Technavio Research. The market has been segmented by distribution channels (hospital pharmacies, retail pharmacies, and online pharmacies), therapy (hormonal therapy, chemotherapy, and others), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). North America is estimated to contribute 47% to the growth of the global market during the forecast period. Moreover, this region's market growth is driven by high-quality healthcare infrastructure..

纽约，2024年1月8日/PRNewswire/--从2023年到2028年，去势抵抗性前列腺癌（CRPC）治疗市场预计将增长59.8亿美元。此外，据Technavio Research称，在预测期内，市场势头将以8.83%的复合年增长率增长。市场已按分销渠道（医院药房、零售药房和在线药房）、治疗（激素治疗、化疗等）和地理位置（北美、欧洲、亚洲和世界其他地区（ROW））进行细分。据估计，在预测期内，北美对全球市场的增长贡献了47%。此外，该地区的市场增长是由高质量的医疗保健基础设施驱动的。。

Continue Reading

继续阅读

Technavio has announced its latest market research report titled Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2024-2028

Technavio宣布了其最新的市场研究报告，题为《2024-2028年全球去势抵抗性前列腺癌（CRPC）治疗市场》

This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read a Free PDF Sample Report

本报告提供了对当前市场情景、最新趋势和驱动因素以及整体市场环境的最新分析。阅读免费PDF示例报告

Company Profile:

公司简介：

Active Biotech AB, Allarity Therapeutics Inc., Amgen Inc., Amneal Pharmaceuticals Inc., Astellas Pharma Inc., Bayer AG, BeiGene Ltd., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Everest Pharmaceuticals Ltd., F. Hoffmann La Roche Ltd., Johnson and Johnson, Medias Klinikum GmbH and Co. KG, Merck KGaA, Novartis AG, Pfizer Inc., Robotic Prostate Centre Cambridge, Sanofi SA, The Focal Therapy Clinic, and Ono Pharmaceutical Co.

Active Biotech AB、Allarity Therapeutics股份有限公司、Amgen股份有限公司、Amneal Pharmaceuticals股份有限公司、Astellas Pharma股份有限公司、Bayer AG、BeiGene有限公司、Daiichi Sankyo Co.有限公司、Dr Reddys Laboratories有限公司、Everest Pharmacetics有限公司、F.Hoffmann La Roche有限公司、Johnson and Johnson、Medias Klinikum GmbH and Co.KG、Merck KGaA、Novartis AG、Pfizer股份有限公司、Robotic Prostate Centre Cambridge、Sanofi SA、，焦点治疗诊所和小野制药公司。

Ltd.Allarity Therapeutics Inc. - The company offers Castration-Resistant Prostate Cancer CRPC treatments such as LiPlaCis and Irofulven, in Phase II trials.    To gain access to more company profiles available with Technavio, buy the report!Castration-Resistant Prostate Cancer (CRPC) Treatment Market: Segmentation AnalysisThe hospital pharmacies segment is estimated to witness significant growth during the forecast period. A specific category of pharmacies operating within the premises of a healthcare facility is included in this hospital pharmacy segment.Learn about the contribution of each segment summarized in concise infographics and thorough descriptions.

Allarity Therapeutics Inc.-该公司在II期试验中提供去势抵抗性前列腺癌CRPC治疗，如LiPlaCis和Irofulven。要访问Technavio提供的更多公司简介，请购买该报告！去势抵抗性前列腺癌（CRPC）治疗市场：细分分析据估计，医院药房细分市场在预测期间将出现显着增长。在医疗保健设施内经营的特定类别的药房包括在该医院药房部分。通过简明的信息图表和详尽的描述，了解每个细分市场的贡献。

View a Free PDF Sample ReportCastration-Resistant Prostate Cancer (CRPC) Treatment Market: Market DynamicsKey DriverThe increasing Early detection of prostate cancer is a key factor driving market growth. This growth has intensified the use of Androgen Deprivation Therapy (ADT), Chemotherapy (including Docetaxel and cabazitaxel), and novel medications like Abiraterone Acetate, Enzalutamide, Radium-223 Dichloride.

查看免费PDF样本报告去势抵抗性前列腺癌（CRPC）治疗市场：市场动态关键驱动因素前列腺癌早期检测的增加是推动市场增长的关键因素。这种增长加强了雄激素剥夺疗法（ADT），化疗（包括多西紫杉醇和卡巴他赛）以及新型药物如醋酸阿比特龙，恩扎鲁胺，镭-223二氯化物的使用。

Additionally, the emergence of immunotherapy, PARP Inhibitors such as Olaparib, and advancements in targeted therapies focusing on Prostate-Specific Membrane Antigen (PSMA) are further catalyzing innovative treatment approaches for CRPC.Leading TrendThe evolution of CRPC treatm.

此外，免疫疗法，PARP抑制剂（如Olaparib）的出现以及针对前列腺特异性膜抗原（PSMA）的靶向治疗的进展进一步催化了CRPC的创新治疗方法。主导趋势CRPC治疗的演变。

CAGR of the market during the forecast period

预测期内市场的复合年增长率

Detailed information on factors that will drive the growth of the castration-resistant prostate cancer (CRPC) treatment market between 2023 and 2028.

有关2023年至2028年间推动去势抵抗性前列腺癌（CRPC）治疗市场增长的因素的详细信息。

Precise estimation of the castration-resistant prostate cancer (CRPC) treatment market size and its contribution to the market in focus on the parent market

精确估计去势抵抗性前列腺癌（CRPC）治疗市场规模及其对母体市场的贡献

Accurate predictions about upcoming trends and changes in consumer behavior

准确预测消费者行为的未来趋势和变化

Growth of the castration-resistant prostate cancer (CRPC) treatment market across North America, Europe, Asia, and ROW

北美、欧洲、亚洲和世界其他地区去势抵抗性前列腺癌（CRPC）治疗市场的增长

A thorough analysis of the market's competitive landscape and detailed information about companies

对市场竞争格局和公司详细信息的透彻分析

Comprehensive analysis of factors that will challenge the growth of castration-resistant prostate cancer (CRPC) treatment market companies.

全面分析将挑战去势抵抗性前列腺癌（CRPC）治疗市场公司增长的因素。

ToC:Executive SummaryMarket LandscapeMarket SizingHistoric Market SizesFive Forces AnalysisMarket Segmentation by Distribution ChannelMarket Segmentation by TherapyMarket Segmentation by GeographyCustomer LandscapeGeographic LandscapeDrivers, Challenges, & TrendsCompany LandscapeCompany AnalysisAppendixAbout TechnavioTechnavio is a leading global technology research and advisory company.

ToC：执行摘要市场景观市场规模历史市场规模五力分析通过分销渠道进行市场细分通过地理进行市场细分客户景观地理景观驱动因素、挑战和趋势公司景观公司分析附录关于TechnavioTechnavio是一家领先的全球技术研究和咨询公司。

Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries.

他们的研究和分析侧重于新兴市场趋势，并提供可行的见解，以帮助企业识别市场机会并制定有效的战略来优化其市场地位。Technavio的报告库拥有500多名专业分析师，由17000多份报告和统计数据组成，涵盖了50个国家的800多种技术。

Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.ContactsTechnavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: [email protected]Website: www.technavio.comSOURCE Technavio.

他们的客户群包括各种规模的企业，包括100多家财富500强公司。这一不断增长的客户群依靠Technavio的全面覆盖范围、广泛的研究和可行的市场见解来确定现有和潜在市场的机会，并评估其在不断变化的市场情景中的竞争地位。ContactsTechnavio Research Jesse MaidaMedia&Marketing ExecutiveUS：+1 844 364 1100UK：+44 203 893 3200电子邮件：[受电子邮件保护]网站：www.technavio.comSOURCE technavio。